Evidence map›Paper›PMID 39544713›Full record

ArticleInternational journal of clinical and experimental pathology2024

Comparative analyses of erythroblast transformation specific-1 related gene expression before and after neoadjuvant bevacizumab therapy for newly diagnosed glioblastoma.

Ai Iwauchi, Nei Fukasawa, Jun Takei, Miku Maeda, Kyoichi Tomoto, Akihiko Teshigawara, Yohei Yamamoto, Yasuharu Akasaki, Yuzuru Hasegawa, Yuichi Murayama and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical and experimental pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ai IwauchiDepartment of Pathology, The Jikei University School of Medicine Tokyo, Japan.
Nei FukasawaDepartment of Pathology, The Jikei University School of Medicine Tokyo, Japan.
Jun TakeiDepartment of Neurosurgery, The Jikei University School of Medicine Tokyo, Japan.
Miku MaedaDepartment of Pathology, The Jikei University School of Medicine Tokyo, Japan.
Kyoichi TomotoDepartment of Neurosurgery, The Jikei University School of Medicine Kashiwa Hospital Tokyo, Japan.
Akihiko TeshigawaraDepartment of Neurosurgery, The Jikei University School of Medicine Kashiwa Hospital Tokyo, Japan.
Yohei YamamotoDepartment of Neurosurgery, The Jikei University School of Medicine Kashiwa Hospital Tokyo, Japan.
Yasuharu AkasakiDepartment of Neurosurgery, The Jikei University School of Medicine Tokyo, Japan.
Yuzuru HasegawaDepartment of Neurosurgery, The Jikei University School of Medicine Kashiwa Hospital Tokyo, Japan.
Yuichi MurayamaDepartment of Neurosurgery, The Jikei University School of Medicine Tokyo, Japan.
Keisuke MiyakeDepartment of Neurological Surgery, Faculty of Medicine, Kagawa University Graduate School of Medicine Tokyo, Japan.
Masayuki ShimodaDepartment of Pathology, The Jikei University School of Medicine Tokyo, Japan.
Toshihide TanakaDepartment of Neurosurgery, The Jikei University School of Medicine Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of the present study was to investigate the expression of erythroblast transformation specific-1 related gene (ERG) in patients with glioblastoma (GB) before and after bevacizumab (Bev) therapy as a predictive and prognostic biomarker.

methodsThe present study used 58 GB tissues from 29 patients in 3 settings. Sixteen tumors were removed after neoadjuvant Bev administration (neoBev) and 13 represented newly diagnosed GB without previous Bev treatment (naïve Bev). Another 29 specimens of recurrence were obtained from salvage surgery or autopsy.

resultsImmunohistochemical analysis showed both vessel density (VD) and ERG score were decreased in neoBev compared with naïve Bev. VD and ERG score tended to be lower at recurrence than at initial surgery (P=0.0026 and P=0.1338, respectively). In the naïve Bev and neoBev cohorts, overall survival (OS) with high and low expressions of ERG was comparable (P=0.7516 and P=0.3862, respectively).

conclusionHigh expression of ERG in GB with naïveBev was significantly reduced with Bev, but not changed in refractoriness. Stratification of ERG expression levels might provide a useful predictive biomarker for GB treated with Bev.

Indexed as

Endothelial cellerythroblast transformation specific-1 related gene (ERG)glioblastomamicrovessel densityneoadjuvant bevacizumabvascular normalization

Identifiers

PMID39544713
PMCPMC11558313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.